The anti-CTLA-4 antibody ipilimumab has shown durable anti-tumor activity and prolonged survival in patients with advanced melanoma, but is prone to immune-related adverse events (IAEs) (Buchbinder et al., 2016). This evidence concerns the gene CTLA4 and melanoma.